Skip to main content
Mayinglong Pharmaceutical Group Co.,Ltd logo

Mayinglong Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600993 ISIN · CNE000001HN2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 931 across all filing types
Latest filing 2014-04-24 Annual Report
Country CN China
Listing Shanghai Stock Exchange 600993

About Mayinglong Pharmaceutical Group Co.,Ltd

https://www.mayinglong.cn/

Mayinglong Pharmaceutical Group Co.,Ltd. is a long-established enterprise specializing in the research, development, and production of Traditional Chinese Medicine (TCM). Founded in 1582, the company is widely recognized for its expertise in proctology, maintaining a dominant market position with its signature hemorrhoid ointments and suppositories. Its product portfolio also includes ophthalmic preparations, dermatological treatments, and gastrointestinal medicines. The company integrates traditional medicinal formulas with modern manufacturing technologies to provide healthcare solutions. Beyond pharmaceuticals, Mayinglong has expanded into healthcare services, including specialized hospitals and personal care products, focusing on the integration of clinical treatment and health management.

Recent filings

Filing Released Lang Actions
审计报告
Annual Report Classification · 95% confidence The document contains detailed financial statements including balance sheets and profit and loss statements for the years ending December 31, 2013 and 2012. It includes comprehensive financial data such as assets, liabilities, equity, revenues, expenses, and net profit figures. The length of the document is substantial (15,000 characters) and it is not merely an announcement or a certification. The presence of full financial statements and notes indicates this is a full annual financial report. Therefore, this document fits the definition of an Annual Report (10-K).
2014-04-24 Chinese
2013年度审计委员会工作报告
Audit Report / Information Classification · 95% confidence The document is titled '2013 年度审计委员会工作报告' which translates to '2013 Annual Audit Committee Work Report'. It details the activities of the audit committee for the year 2013, including oversight of external auditors, internal audit guidance, review of financial reports, evaluation of internal controls, and coordination between management and auditors. The document references regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange, indicating it is a formal audit committee report. The content focuses on audit committee work rather than the full annual report or standalone audit opinion. Given the nature and content, this fits best under 'Audit Report / Information (AR)' which includes standalone audit reports and related audit committee reports, excluding full annual reports. The document length is short (1527 characters) but contains substantive audit committee information, not just an announcement or certification. Therefore, the classification is AR with high confidence. FY 2013
2014-04-24 Chinese
2013年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Evaluation Report" for the year 2013 by 马应龙药业集团股份有限公司. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2013, covering financial and non-financial internal control deficiencies, internal control scope, control activities, organizational structure, and compliance with regulatory requirements. The document is detailed and contains substantive content about internal control evaluation, including standards, scope, and conclusions. It is not an announcement or a brief summary but a full report on internal control evaluation. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles and internal control evaluations, excluding full annual reports. There is no indication that this is a full Annual Report (10-K) or an Interim Report (IR), nor is it a simple announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2013
2014-04-24 Chinese
第八届董事会第四次会议决议公告
Annual Report Classification · 95% confidence The document is a detailed announcement of resolutions passed at the fourth meeting of the eighth board of directors of 马应龙药业集团股份有限公司. It includes approval of various reports such as the General Manager's Work Report, Board Work Report, Independent Directors' Report, Audit Committee Report, 2013 Financial Statements, Profit Distribution Plan, 2013 Annual Report and Summary, Internal Control Evaluation Report, Social Responsibility Report, and other governance matters including amendments to the Articles of Association. The document contains substantive financial data for 2013, including revenue, net profit, earnings per share, equity, assets, and cash flow figures, as well as audit opinions. It also discusses profit distribution and dividend proposals. The presence of comprehensive financial data and multiple management and audit reports indicates this is a full annual report or equivalent comprehensive yearly disclosure. The document is over 5,000 characters and contains actual financial statements and analysis, not just an announcement or summary. Therefore, it fits the definition of an Annual Report (10-K). FY 2013
2014-04-24 Chinese
关于出资设立小额贷款公司的关联交易公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding a related-party transaction where the company (马应龙药业集团股份有限公司) is investing in a small loan company jointly with a related party (中国宝安集团股份有限公司). It includes information about the transaction, the approval process by the board, independent directors' opinions, and compliance with regulatory requirements. The document is not a financial report, earnings release, or management discussion but rather a formal announcement of a significant related-party transaction. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about a corporate transaction that does not fall under other specific categories like M&A or Capital/Financing Update. The document length is 2710 characters, which is relatively short and typical for such announcements. Therefore, the best classification is Regulatory Filings (RNS).
2014-04-24 Chinese
第八届监事会第四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the supervisory board of Mayinglong Pharmaceutical Group Co., Ltd. It includes approvals of the 2013 Annual Report and Summary, Supervisory Board Work Report, 2013 Internal Control Evaluation Report, and the 2014 First Quarter Report. The document is relatively short (1138 characters) and primarily announces the passing of these reports rather than containing the full reports themselves. It also mentions that some items require submission to the annual shareholders meeting. Given the short length and nature of the content, this is an announcement of meeting resolutions and approvals rather than the full reports. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution notice rather than the full Annual Report (10-K) or Interim Report (IR).
2014-04-24 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.